<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01526577</url>
  </required_header>
  <id_info>
    <org_study_id>LG-PYCL001</org_study_id>
    <secondary_id>LC23-1306</secondary_id>
    <nct_id>NCT01526577</nct_id>
  </id_info>
  <brief_title>Study of LC23-1306 in Healthy Male Subjects</brief_title>
  <official_title>A Dose Blocked-randomized, Double-blind, Active and Placebo Controlled, Single and Multiple Dosing, Dose-escalation Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics and Food Effect</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Life Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Life Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a dose block-randomized, double-blind, active and placebo controlled, single and
      multiple dosing, dose-escalation study to evaluate tolerability, safety and
      pharmacokinetic/pharmacodynamic characteristics. Adverse events, physical examinations, vital
      signs, ECG and laboratory tests will be conducted for safety/tolerability evaluation and
      serial blood samples and urine collections for pharmacokinetic and pharmacodynamic
      evaluations will be conducted at specified time points.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events of LC23-1306</measure>
    <time_frame>7 days (plus or minus 1 day)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamic Measurement</measure>
    <time_frame>1D 0, 2, 8, 24h for single dose study / 1D and 7D 0, 2, 8, 12, 24h for multiple dose study</time_frame>
    <description>Inhibition of platelet aggregation (IPA) was analized by the platelet aggregation test.
* Among the time points that platelet aggregation rate was meausred, the result only at 8h post dosing was provided in result section.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Platelet Aggregation Test, Bleeding Test</measure>
    <time_frame>pre-dose, up to 1 day post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>pre-dose, up to 3 days post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">113</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>LC23-1306</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>experimental drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>LC23-1306 placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ticagrelor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>active comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LC23-1306</intervention_name>
    <description>LC23-1306 10, 30, 100, 200, 400, 600 mg Placebo 10, 30, 100, 200, 400, 600 mg</description>
    <arm_group_label>LC23-1306</arm_group_label>
    <other_name>antiplatelet agent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>LC23-1306 placebo</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>Ticagrelor 90mg</description>
    <arm_group_label>Ticagrelor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male subjects between the ages of 20 and 50 years at screening

          2. Subjects with Body Mass Index (BMI) between 18.0 (inclusive) and 27.0 kg/m2
             (exclusive); and a total body weight between 55 kg (inclusive) and 90 kg (exclusive).
             BMI (kg/m2) = body weight (kg)/ {height (m)}2.

          3. Subject is informed of the investigational nature of this study and voluntarily agrees
             to participate in this study and signs an Institutional Review Board (IRB) - approved
             informed consent prior to performing any of the screening procedures.

          4. Findings within the range of clinical acceptability in medical history and physical
             examination, and laboratory results within the laboratory reference ranges for the
             relevant laboratory tests
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <study_first_submitted>January 20, 2012</study_first_submitted>
  <study_first_submitted_qc>February 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2012</study_first_posted>
  <results_first_submitted>May 20, 2015</results_first_submitted>
  <results_first_submitted_qc>November 3, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 13, 2018</results_first_posted>
  <last_update_submitted>November 3, 2017</last_update_submitted>
  <last_update_submitted_qc>November 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>phase1</keyword>
  <keyword>healthy subjects</keyword>
  <keyword>antiplatelet agent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ticagrelor</mesh_term>
    <mesh_term>Platelet Aggregation Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment location: Seoul University Hospital
Recruitment period:
Single dose study recruitment period: 12Mar2012 ~ 18Sep2012
Muti-dose study recruitment period: 02Dec2012 ~ 05Aug2013</recruitment_details>
      <pre_assignment_details>The subjects were enrolled in single dose study and multiple study separately. The subject enrolled in single dose study was not allowed to be enrolled in multiple dose study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Single Dosing LC23-1306</title>
          <description>experimental drug LC23-1306 10, 30, 100, 200, 400, 600 mg</description>
        </group>
        <group group_id="P2">
          <title>Single Dosing Placebo</title>
        </group>
        <group group_id="P3">
          <title>Multiple Dosing LC23-1306</title>
          <description>LC23-1306 100, 200, 400, 600mg</description>
        </group>
        <group group_id="P4">
          <title>Multiple Dosing Placebo</title>
        </group>
        <group group_id="P5">
          <title>Multiple Dosing Ticagrelor 90mg</title>
          <description>Active comparator</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="49">1 more subject enrolled as a substitute for 1 withdrawn subject before the administration.</participants>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="33">1 more subject enrolled as a substitute for 1 withdrawn subject before the administration.</participants>
                <participants group_id="P4" count="9">1 more subject enrolled as a substitute for 1 withdrawn subject before the administration.</participants>
                <participants group_id="P5" count="10">2 more subjects were enrolled as the substitutes for 2 withdrawn subjects before the administration.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="32"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Single Dosing LC23-1306</title>
          <description>Experimental drug LC23-1306 10, 30, 100, 200, 400, 600 mg</description>
        </group>
        <group group_id="B2">
          <title>Single Dosing Placebo</title>
        </group>
        <group group_id="B3">
          <title>Multiple Dosing LC23-1306</title>
          <description>Experimental drug LC23-1306 100, 200, 400, 600mg</description>
        </group>
        <group group_id="B4">
          <title>Multiple Dosing Placebo</title>
        </group>
        <group group_id="B5">
          <title>Multiple Dosing Ticagrelor 90mg</title>
          <description>Active comparator</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="49"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="33"/>
            <count group_id="B4" value="9"/>
            <count group_id="B5" value="10"/>
            <count group_id="B6" value="113"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27" spread="4"/>
                    <measurement group_id="B2" value="27" spread="3"/>
                    <measurement group_id="B3" value="28" spread="4"/>
                    <measurement group_id="B4" value="26" spread="4"/>
                    <measurement group_id="B5" value="31" spread="6"/>
                    <measurement group_id="B6" value="27" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adverse Events of LC23-1306</title>
        <time_frame>7 days (plus or minus 1 day)</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacodynamic Measurement</title>
        <description>Inhibition of platelet aggregation (IPA) was analized by the platelet aggregation test.
* Among the time points that platelet aggregation rate was meausred, the result only at 8h post dosing was provided in result section.</description>
        <time_frame>1D 0, 2, 8, 24h for single dose study / 1D and 7D 0, 2, 8, 12, 24h for multiple dose study</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LC23-1306</title>
            <description>experimental drug
LC23-1306: LC23-1306 10, 30, 100, 200, 400, 600 mg Placebo 10, 30, 100, 200, 400, 600 mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>LC23-1306 placebo
placebo: LC23-1306 placebo</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor</title>
            <description>active comparator
Ticagrelor: Ticagrelor 90mg</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamic Measurement</title>
          <description>Inhibition of platelet aggregation (IPA) was analized by the platelet aggregation test.
* Among the time points that platelet aggregation rate was meausred, the result only at 8h post dosing was provided in result section.</description>
          <units>percentage of platelet inhibition</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="91.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC</title>
        <time_frame>pre-dose, up to 3 days post-dose</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Platelet Aggregation Test, Bleeding Test</title>
        <time_frame>pre-dose, up to 1 day post-dose</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>LC23-1306</title>
          <description>Test drug.</description>
        </group>
        <group group_id="E2">
          <title>Ticagrelar</title>
          <description>Active comparator</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea and so on.</sub_title>
                <description>One of the related AE.</description>
                <counts group_id="E1" events="50" subjects_affected="43" subjects_at_risk="82"/>
                <counts group_id="E2" events="13" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dong Yeop Shin</name_or_title>
      <organization>LG Life Sciences</organization>
      <phone>82 2 6924 3114</phone>
      <email>dongyeopshin@lgls.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

